LUNG - Pulmonx Corp logo

LUNG

Pulmonx Corp

Pulmonx Corporation develops minimally invasive treatments for severe emphysema, primarily through its Zephyr Endobronchial Valve and Chartis Pulmonary Assessment System. Its LungTraX Platform provides cloud-based analysis for enhanced patient assessment and treatment.

⚕️ Healthcare NASDAQ Listed 2020 $ USD
$1,000 invested 5 years ago $60today

Score Overview

1 Year
Score
Net Growth10.90%
Net TrendGrew
Net Income Consistency
Rev Growth-3.38%
Rev TrendShrank
Revenue Consistency
5 Years
Score5.6
Net Growth1.12%
Net Trend60%
Net Income Consistency
Rev Growth80.61%
Rev Trend80%
Revenue Consistency
All Time
Score
Net Growth-49.28%
Net Trend50%
Net Income Consistency
Rev Growth167.14%
Rev Trend83%
Revenue Consistency

See the full market ranking →

Pulmonx Corp fundamental performance

Between 2020 and 2025, revenue grew from $ 32M to $ 90M and net income went from -$ 32M to -$ 54M. Revenue increased in 4 of those 5 years; net income in 3.

Pulmonx Corp currently holds a 5-year HDB Score of 5.6 out of 10. How the HDB Score is calculated.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 2.29
1 Year2025-08-12
$ 1.5944.03%
5 Years2021-08-12
$ 37.93-93.96%
All Time2020-10-01
$ 39.31-94.17%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 87M-$ 48M$ 55M
2025$ 90M-$ 54M$ 70M
2024$ 83M-$ 56M$ 101M
2023$ 68M-$ 60M$ 117M
2022$ 53M-$ 58M$ 141M
2021$ 48M-$ 48M$ 180M
IPO2020$ 32M-$ 32M$ 231M

Explore beyond LUNG

You're looking at Pulmonx Corp. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies